Fig. 3
From: Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer
S109 inhibits proliferation and colony formation of SKOV-3 cells. a Representative EdU analysis of cell proliferation after S109 treatment. b Quantitativeresults of EdU incorporation assay. c S109 inhibits the colony formation of SKOV-3 cells. d Quantitative results of clonogenic assay. The percentage of proliferative cells or colony formation were normalized to that of the control group. All the data are presented as mean ± SEM in three repeats (*P < 0.05)